Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma-Reference-Cited by-同舟云学术

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Published:2021-02 Issue:2 Volume:27 Page:256-263
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Rozeman E. A.,Hoefsmit E. P.^ORCID,Reijers I. L. M.,Saw R. P. M.^ORCID,Versluis J. M.,Krijgsman O.,Dimitriadis P.^ORCID,Sikorska K.,van de Wiel B. A.,Eriksson H.,Gonzalez M.,Torres Acosta A.,Grijpink-Ongering L. G.,Shannon K.^ORCID,Haanen J. B. A. G.^ORCID,Stretch J.,Ch’ng S.,Nieweg O. E.^ORCID,Mallo H. A.,Adriaansz S.,Kerkhoven R. M.,Cornelissen S.,Broeks A.,Klop W. M. C.,Zuur C. L.,van Houdt W. J.,Peeper D. S.^ORCID,Spillane A. J.^ORCID,van Akkooi A. C. J.,Scolyer R. A.^ORCID,Schumacher T. N. M.^ORCID,Menzies A. M.,Long G. V.,Blank C. U.^ORCID

Funder

Bristol-Myers Squibb

Funding was paid to the Netherlands Cancer Institute.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-020-01211-7.pdf

Reference39 articles.

1. Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655–1661 (2018).

2. Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948–960 (2019).